Northeast Pharmaceutical Group Co Ltd

Northeast Pharmaceutical Group maintains a conservative capital structure with a debt-to-equity ratio of 0.45 and a current ratio of 1.15. The balance sheet shows total assets of 12.89 billion CNY against total liabilities of 7.36 billion CNY, resulting in total equity of 5.53 billion CNY. Long-term debt stands at 2.48 billion CNY. Despite positive operating cash flow of 1.11 billion CNY and free cash flow of 465.22 million CNY, the company carries a net cash deficit after accounting for total debt, indicating a medium liquidity risk profile.

Profitability metrics reveal thin margins relative to the asset base. The company reported net income of 260.07 million CNY on revenue of 7.07 billion CNY, yielding a return on equity (ROE) of 1.79% and a return on assets (ROA) of 0.77%. The price-to-earnings ratio of 66.0 suggests the market is pricing in future growth or expects current earnings to be non-representative, while the price-to-book ratio of 1.18 indicates the market values the company close to its book value. The EV/EBITDA multiple of 52.49 is elevated, reflecting the low earnings yield relative to enterprise value.

Revenue concentration and segment details are not explicitly provided in the available data, preventing a detailed analysis of product mix or geographic exposure. The company operates within the broader pharmaceuticals industry, where revenue streams are typically diversified across therapeutic areas, but specific segment contributions cannot be quantified from the current snapshot.

Growth trajectory analysis is limited by the absence of historical period data in the input. Without multi-year revenue or net income trends, it is not possible to assess the company's historical growth rate or momentum. The current revenue base of 7.07 billion CNY provides a scale reference, but year-over-year changes remain undisclosed.

Risk assessment highlights a medium liquidity risk and low dilution risk. The key flag notes that net cash is negative after subtracting total debt, which may constrain financial flexibility despite positive operating cash flows. The low dilution risk suggests that share count stability is likely, with basic and diluted shares outstanding both at 1.43 billion.

Recent events, filing observations, and news transcripts are not available in the provided data. Consequently, no recent corporate actions, regulatory updates, or management signals can be incorporated into the analysis. The assessment relies solely on the static financial and valuation snapshots provided.

The company generates strong free cash flow of 465 million CNY, supporting financial flexibility despite recent earnings volatility.

Cash conversion ratio of 7.54 ranks best-in-class among 857 pharmaceutical peers, indicating superior operational efficiency.

Debt-to-equity ratio of 0.45 is below the cohort median of 0.18, suggesting a manageable leverage position relative to peers.

Capex intensity is above the 75th percentile, indicating lower capital expenditure requirements relative to revenue generation.

Dilution risk is assessed as low, providing some protection for existing shareholders against equity value erosion.

Credit risk is flagged as high, raising concerns about the company's ability to meet its financial obligations.